齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性比较研究

The Effect and Safety of Ziprasidone and Olanzapine in the Early Treatment of Schizophrenia

目的:对比在早期精神分裂症(Early schizophrenia,ES)的治疗中,齐拉西酮、奥氮平两种药物所具有的疗效和安全性。方法:择取2013年5月—2016年5月期间于笔者所在医院治疗的80例患者,按照临床用药的不同进行分组:选用奥氮平的40例患者归入对照组,选用齐拉西酮的40例患者归入研究组。组间对比疗效与安全性。结果:研究组在疗效、CGI评分、PANSS减分率、TESS评分上均优于对照组,治疗前后各项糖脂代谢指标的变化小于对照组,统计学有差异(P<0.05)。结论:为ES患者使用齐拉西酮可以取得比奥氮平更加显著的治疗效果,且安全性更高。

Objective: To compare the efficacy and safety of ziprasidone and olanzapine in the treatment of schizophrenia. Methods: 80 patients inthe author's hospital from May 2013 to May 2016 were divided into two groups: 40 patients with olanzapine as the control group, 40 patients withziprasidone treatment refer to treatment group. Efficacy and safety tbetween the two groups were compared. Results: Effect, CGI score, PANSS rate,TESS score in the treatment groups were better than control group. The changes of glucose and lipid metabolism before and after treatment werelower in the treatment group compared with control group (P<0.05). Conclusion: Patients with ziprasidone treatment may obtain better effect andhigher safety compared with olanzapine treatment